BTAI vs ECL · rev $2.3M vs P/E 35, rev $4.01B
BioXcel Therapeutics Inc (BTAI) versus Ecolab Inc (ECL) — a side-by-side from cached financials, not a winner call.
BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.
Ecolab Inc (ECL) is a specialty chemicals company listed on US.
Latest reported BTAI revenue for 2024-12-31 was $2.3M. Net income was -$59.6M. Revenue was up 64.2% from 2023-12-31 to 2024-12-31. BTAI currently screens at market cap $36.1M.
Latest reported ECL revenue for 2024-12-31 was $4.01B. Net income was $2.13B. Revenue was up 0.2% from 2024-09-30 to 2024-12-31. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
BTAI currently screens at market cap $36.1M. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
Not investment advice. Open the BTAI and ECL stock pages for the full models.
Not investment advice.